Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma

Abstract

BackgroundOmentin is related with metabolic syndrome and obesity. Pancreatic adenocarcinoma (PA) is a lethal and obesity-linked malignancy. This study was conducted to investigate the serum levels of omentin in patients with PA and the relationship with tumor progression and known prognostic parameters.Material and methodsSerum samples were obtained from thirty-three patients on first admission before any treatment. Age, sex and body mass index (BMI) matched 30 healthy controls were included in the analysis. Both serum omentin levels were measured using enzyme-linked immunosorbent assay (ELISA).ResultsThe median age at diagnosis was 59 years (32–84 years). Twenty (61%) patients were men and the remaining were women. The most common metastatic site was liver in 23 patients with metastasis (n = 19, 83%). Thirty-nine percent of 23 metastatic patients who received palliative chemotherapy (CTx) were CTx–responsive. Median overall survival of the whole group was 41.3 ± 8.3 weeks [95% confidence interval (CI) = 25–58 weeks]. The baseline serum omentin levels were significantly higher in patients with PA than in the control group (p < 0.001). Serum omentin levels were significantly higher in patients with larger pathologic tumor size compared with smaller size (p = 0.03). Conversely, serum omentin concentration was found to have no prognostic role on survival (p = 0.54).ConclusionSerum levels of omentin may have a good diagnostic role in patients with PA.

Association of Omentin-1 with Oxidative Stress and Clinical Significances in Patients with Breast Cancer

“…The role of omentin-1, an important adipokine produced by adipose tissue, is controversial in various cancers. [19][20][21] Studies showed that the serum level of omentin-1 is elevated in chronic and acute pancreatitis, prostate and colorectal cancer, while it is decreased in patients with breast, bladder and renal cell cancers. 21,34,35 The results of studies suggest that omentin-1 may play different roles in tumorigenesis and anti-oncogenic pathways in cancer.…”

“…18 Researchers showed that the serum level of omentin-1 is elevated in chronic and acute pancreatitis, while it is decreased in patients with polycystic ovary syndrome and BC. [19][20][21] Genetics studies have demonstrated that there are significant relationships between omentin-1 109Asp/Val genotypes and BC risk. 22 Despite all the available data, there is no evidence for the association of omentin-1 with oxidative stress and clinical significance in patients with BC.…”

Role of omentin and vaspin in metabolic diseases in association with psoriasis

“…Higher adipokine concentrations have also been detected in patients with pancreatic adenocarcinoma, with a positive correlation found between an increase in its concentration and tumour mass. Such observations may suggest the use of the protein in screening tests for early cancer detection [24][25][26][27]. Omentin is also attracting a growing interest in the context of the development of cardiovascular diseases.…”

“…Większe stężenie adipokiny stwierdzono także u chorych z gruczolakorakiem trzustki, a wzrost jej stężenia dodatnio korelował z masą guza. Obserwacje te mogą sugerować wykorzystanie tego białka w badaniach przesiewowych w kierunku wczesnego wykrycia nowotworów [24][25][26][27]. Omentyna wzbudza coraz większe zainteresowanie w związku z choro-Dermatology Review/Przegląd Dermatologiczny 2017/5 lium, halting oxidative stress and inflammation through TNF-α inhibition, suppression of monocyte adhesion to endothelial cells by inhibiting the expression of ICAM-1 and VCAM-1 [28,29].…”

Omentin – a novel biomarker in medicine? (Part 2)

“…Pomiaru stężenia omentyny-1 we krwi dokonywano przed rozpoczęciem leczenia. Jej stężenie było wyższe u pacjentów z gruczolakorakiem trzustki niż u pacjentów zdrowych i było wyższe u pacjentów z guzem o większych rozmiarach niż u pacjentów z guzem małej wielkości [33].…”